ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

ClinicalTrials.gov ID: NCT06253923

Public ClinicalTrials.gov record NCT06253923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).

Study identification

NCT ID
NCT06253923
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
SHINKEI Therapeutics, Inc
Industry
Enrollment
45 participants

Conditions and interventions

Interventions

  • Amantadine Hydrochloride Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2024
Primary completion
Jul 30, 2025
Completion
Jul 31, 2025
Last update posted
Jul 14, 2025

2024 – 2025

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Los Angeles General Medical Center Los Angeles California 90033
UC Davis Medical Center Sacramento California 95817
UF Health Heart and Vascular Hospital Gainesville Florida 32608
Tampa General Hospital Tampa Florida 33606
Maine Medical Center Portland Maine 04102
Wayne State University Detroit Michigan 48201
Barnes Jewish Hospital St Louis Missouri 63110
Hackensack Meridian Health Jersey Shore University Medical Center Neptune City New Jersey 07753
University of New Mexico Hospital Albuquerque New Mexico 87106
Department of Neurology, Duke University School of Medicine Durham North Carolina 27705
Penn Presbyterian Medical Center Philadelphia Pennsylvania 19104
McGovern Medical School, University of Texas Health Science Center Houston Texas 77030
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06253923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 14, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06253923 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →